Literature DB >> 2997567

Combined administration of human corticotropin-releasing factor and lysine vasopressin induces cortisol escape from dexamethasone suppression in healthy subjects.

U von Bardeleben, F Holsboer, G K Stalla, O A Müller.   

Abstract

Inadequate suppression of plasma cortisol after 1-2 mg dexamethasone is frequently observed in depressive patients. To further investigate the pathophysiology underlying cortisol nonsuppression after dexamethasone we compared cortisol and corticotropin (ACTH) response to human corticotropin-releasing factor (h-CRF), lysine vasopressin (LVP), and a concurrent administration of both peptides after pretreatment with 1.5 mg dexamethasone in six male controls. Neither h-CRF nor LVP were able to produce a marked elevation of dexamethasone suppressed plasma cortisol and ACTH. If both peptides were administered in combination, a substantial escape of plasma cortisol from dexamethasone suppression was observed. ACTH responses changed in concordance with those of cortisol indicating that the LVP-CRF interaction takes place at the pituitary level. Our finding is consistent with a multihormonal control of pituitary-adrenal activity and bears several implications for interpretation of dexamethasone suppression test results in depressive illness.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997567     DOI: 10.1016/0024-3205(85)90480-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  10 in total

Review 1.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 2.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

3.  Concomitant infusion of ovine corticotropin-releasing hormone does not prevent suppression of the hypothalamus-pituitary-adrenal axis by dexamethasone in male rats.

Authors:  T S Huang
Journal:  J Endocrinol Invest       Date:  1997 Jul-Aug       Impact factor: 4.256

Review 4.  Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity.

Authors:  F Holsboer
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions.

Authors:  Akito Tanoue; Shuji Ito; Kenji Honda; Sayuri Oshikawa; Yoko Kitagawa; Taka-Aki Koshimizu; Toyoki Mori; Gozoh Tsujimoto
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

6.  Effect of aspirin on hypothalamic-pituitary-adrenal function and on neuropsychological performance in healthy adults: a pilot study.

Authors:  Stuart Watson; Kate Horton; Samantha Bulmer; Jane Carlile; Ciaran Corcoran; Peter Gallagher; I Nicol Ferrier
Journal:  Psychopharmacology (Berl)       Date:  2009-04-29       Impact factor: 4.530

7.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 8.  Psychoneuroendocrine research in depression. II. Hormonal responses to releasing hormones as a probe for hypothalamic-pituitary-endorgan dysfunction.

Authors:  K P Lesch; R Rupprecht
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

Review 9.  [Depression and stress: is there an endophenotype?].

Authors:  Andrea Feijo Mello; Mario Francisco Juruena; Carmine M Pariante; Audrey R Tyrka; Lawrence H Price; Linda L Carpenter; Jose Alberto Del Porto
Journal:  Braz J Psychiatry       Date:  2007-05       Impact factor: 2.697

10.  Lithium monotherapy increases ACTH and cortisol response in the DEX/CRH test in unipolar depressed subjects. A study with 30 treatment-naive patients.

Authors:  Tom Bschor; Dirk Ritter; Patricia Winkelmann; Sebastian Erbe; Manfred Uhr; Marcus Ising; Ute Lewitzka
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.